Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmablast | 5 studies | 31% ± 18% | |
| B cell | 4 studies | 22% ± 4% | |
| transit amplifying cell | 4 studies | 25% ± 4% | |
| T cell | 4 studies | 25% ± 5% | |
| CD4-positive, alpha-beta T cell | 4 studies | 35% ± 11% | |
| erythroblast | 3 studies | 36% ± 19% | |
| erythrocyte | 3 studies | 30% ± 11% | |
| CD8-positive, alpha-beta T cell | 3 studies | 28% ± 9% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 32% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| skin | 90% | 483.62 | 1622 / 1809 | 96% | 22.84 | 454 / 472 |
| intestine | 87% | 148.41 | 845 / 966 | 98% | 35.06 | 515 / 527 |
| esophagus | 79% | 151.31 | 1141 / 1445 | 98% | 33.00 | 180 / 183 |
| ovary | 77% | 44.48 | 139 / 180 | 98% | 28.54 | 422 / 430 |
| stomach | 72% | 95.25 | 258 / 359 | 100% | 32.27 | 285 / 286 |
| breast | 77% | 89.13 | 354 / 459 | 94% | 20.62 | 1047 / 1118 |
| uterus | 72% | 45.86 | 122 / 170 | 98% | 41.91 | 452 / 459 |
| lung | 76% | 76.89 | 440 / 578 | 90% | 24.60 | 1035 / 1155 |
| bladder | 67% | 91.14 | 14 / 21 | 94% | 29.13 | 474 / 504 |
| brain | 90% | 95.52 | 2388 / 2642 | 47% | 9.42 | 329 / 705 |
| adrenal gland | 66% | 47.78 | 171 / 258 | 55% | 8.26 | 127 / 230 |
| pancreas | 20% | 12.39 | 67 / 328 | 87% | 12.11 | 155 / 178 |
| liver | 29% | 38.20 | 65 / 226 | 73% | 14.63 | 298 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 45.82 | 29 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 47.58 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 8.07 | 1 / 1 |
| spleen | 97% | 166.77 | 234 / 241 | 0% | 0 | 0 / 0 |
| heart | 92% | 114.75 | 796 / 861 | 0% | 0 | 0 / 0 |
| adipose | 85% | 118.87 | 1022 / 1204 | 0% | 0 | 0 / 0 |
| prostate | 59% | 52.87 | 145 / 245 | 25% | 2.50 | 123 / 502 |
| kidney | 57% | 45.57 | 51 / 89 | 22% | 2.50 | 201 / 901 |
| muscle | 78% | 55.53 | 629 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 75% | 85.53 | 1004 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 56% | 61.62 | 364 / 653 | 16% | 5.15 | 98 / 605 |
| peripheral blood | 66% | 455.89 | 609 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 53% | 4.65 | 42 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0051726 | Biological process | regulation of cell cycle |
| GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
| GO_0005829 | Cellular component | cytosol |
| GO_0048471 | Cellular component | perinuclear region of cytoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0004725 | Molecular function | protein tyrosine phosphatase activity |
| GO_0017018 | Molecular function | myosin phosphatase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0008138 | Molecular function | protein tyrosine/serine/threonine phosphatase activity |
| GO_0004722 | Molecular function | protein serine/threonine phosphatase activity |
| Gene name | CDKN3 |
| Protein name | protein-tyrosine-phosphatase (EC 3.1.3.48) Cyclin-dependent kinase inhibitor 3 splice variant Cyclin-dependent kinase inhibitor 3 (EC 3.1.3.16) (EC 3.1.3.48) (CDK2-associated dual-specificity phosphatase) (Cyclin-dependent kinase interactor 1) (Cyclin-dependent kinase-interacting protein 2) (Kinase-associated phosphatase) Cyclin-dependent kinase inhibitor 3 (EC 3.1.3.16) (EC 3.1.3.48) |
| Synonyms | CIP2 CDI1 KAP |
| Description | FUNCTION: May play a role in cell cycle regulation. Dual specificity CC phosphatase active toward substrates containing either phosphotyrosine or phosphoserine residues . Dephosphorylates CDK2 at 'Thr-160' in a cyclin-dependent manner . . FUNCTION: May play a role in cell cycle regulation. Dual specificity phosphatase active toward substrates containing either phosphotyrosine or phosphoserine residues. . FUNCTION: May play a role in cell cycle regulation. Dual specificity phosphatase active toward substrates containing either phosphotyrosine or phosphoserine residues. . |
| Accessions | G3V1K6 ENST00000395577.2 F8WD24 ENST00000541304.5 F5H232 ENST00000335183.11 [Q16667-1] G3V2J7 ENST00000543789.6 H7C0S3 ENST00000442975.6 [Q16667-2] A0A0S2KP18 ENST00000458126.6 Q16667 ENST00000556102.6 |
